Date |
Time |
Source |
Heading |
4/23/2024 | 09:00 | BW | Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen.. |
4/17/2024 | 09:00 | BW | Leading Institutions Enroll First Alzheimer’s Patients.. |
3/21/2024 | 16:05 | GLOBE | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023.. |
3/21/2024 | 07:26 | IHMARKETNEWS | U.S. Index Futures Rise as Fed’s Dovish Outlook Spurs.. |
3/12/2024 | 09:00 | BW | Hyperfine, Inc. Collaborates with King’s College London to.. |
3/07/2024 | 16:30 | BW | Hyperfine, Inc. to Announce Fourth Quarter and Full Year.. |
2/28/2024 | 16:30 | BW | Hyperfine, Inc. to Present at the Oppenheimer 34th Annual.. |
2/21/2024 | 09:00 | BW | Hyperfine, Inc. Announces Collaboration with Athletic Heart.. |
2/16/2024 | 16:06 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
2/01/2024 | 08:00 | BW | Hyperfine, Inc. Celebrates Breadth of Swoop® System Data.. |
1/09/2024 | 09:00 | BW | Hyperfine, Inc. Launches AI-powered Brain Imaging Software.. |
11/24/2023 | 00:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
11/20/2023 | 18:20 | EDGAR2 | Form 3/A - Initial statement of beneficial ownership of.. |
11/20/2023 | 09:00 | BW | Hyperfine, Inc. Announces Presentations on Clinical.. |
11/17/2023 | 19:34 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
11/16/2023 | 09:00 | BW | Hyperfine, Inc. to Present at the Piper Sandler 35th Annual.. |
11/09/2023 | 16:58 | EDGAR2 | Form 8-K - Current report |
11/09/2023 | 16:43 | EDGAR2 | Form S-3 - Registration statement under Securities Act of.. |
11/09/2023 | 16:14 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
11/09/2023 | 16:10 | EDGAR2 | Form 8-K - Current report |
11/09/2023 | 16:05 | GLOBE | Hyperfine, Inc. Reports Third Quarter 2023 Financial Results |
11/02/2023 | 09:15 | BW | Observational Study Finds That Hyperfine, Inc. Portable MR.. |
10/19/2023 | 16:05 | BW | Hyperfine, Inc. to Announce Third Quarter Financial Results.. |
10/10/2023 | 16:05 | BW | Hyperfine, Inc. Announces Promotions of Two Key Clinical.. |
10/09/2023 | 09:00 | BW | Hyperfine, Inc. Receives FDA Clearance for Updated.. |
10/03/2023 | 16:07 | EDGAR2 | Form 8-K - Current report |
9/07/2023 | 16:05 | BW | Hyperfine, Inc. to Present at Gilmartin Group Emerging.. |
8/17/2023 | 16:45 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
8/17/2023 | 16:44 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
8/14/2023 | 16:16 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
8/14/2023 | 16:11 | EDGAR2 | Form 8-K - Current report |
8/14/2023 | 16:05 | GLOBE | Hyperfine, Inc. Reports Second Quarter 2023 Financial.. |
8/09/2023 | 09:00 | BW | Enrollment Completed for HOPE PMR Pediatric Hydrocephalus.. |
7/24/2023 | 16:13 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
7/24/2023 | 16:05 | BW | Hyperfine, Inc. to Announce Second Quarter Financial Results.. |
7/18/2023 | 16:19 | EDGAR2 | Form 8-K - Current report |
7/18/2023 | 16:05 | BW | Hyperfine, Inc. Announces Promotion of Tom Teisseyre, Ph.D... |
7/11/2023 | 09:00 | BW | Hyperfine, Inc. Launches Observational Study to Define New.. |
6/08/2023 | 09:00 | BW | Hyperfine, Inc. and the International Society for Magnetic.. |
5/18/2023 | 09:00 | BW | Hyperfine, Inc. Receives Grant for an Additional Three Years.. |
5/11/2023 | 16:05 | GLOBE | Hyperfine, Inc. Reports First Quarter 2023 Financial Results |